APP and Alzheimer disease: Considering that NIRKO mice exhibit deregulation of the insulin‐dependent modulation of dopamine metabolism19 and that therapeutics targeting dopamine and serotonin neurotransmission are generally used for BPSD symptoms of AD patients, further studies focusing on neurotransmitters will lead to an understanding of the underlying mechanism of abnormal behavior in APP/IR‐dKI mice.